|Exchange:||NASDAQ national market|
|Stock:||Syneron Medical, Ltd.|
|Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets innovative aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company’s products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and one minimally invasive product for laser-assisted lipolysis. ELOS provides performance advantages over existing technologies that rely solely on optical energy. The Company’s proprietary ELOS technology, which combines optical and electrical energy, enhances the user’s ability to accurately target the tissue to be treated and enables real-time measurement of skin temperature, resulting in increased patient safety and comfort and improved treatment results. It now also offers in connection with the purchases of new VelaShape II™, LipoLite™ and eMatrix™ devices, the Syneron Advantage program which enables physicians to gain access to its facial applications and body shaping technologies at a more affordable price point that are easier to finance in the current economic environment. As of March 1, 2013, its patent portfolio (including patents held by subsidiaries) consisted of 99 issued U.S. patents, and 112 patents applications pending in the U.S. (with an additional 392 applications pending internationally and 112 international patents), related to 180 patent families relating to its technology and products Its products compete against conventional non-light-based treatments, including Botox (neurotoxins) and collagen injections, sclerotherapy, electrolysis, liposuction, chemical peels and microdermabrasion. The Company’s products are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, as well as other regulatory bodies.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.